A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Summary

A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.

Timeline

Start

2012-04

Primary completion

2015-02

Completion

2015-02

Publications

• Lovell DJ, Dare JA, Francis-Sedlak M, Ball J, LaMoreaux BD, Von Scheven E, Reinhardt A, Jerath R, Alpan O, Gupta R, Goldsmith D, Zeft A, Naddaf H, Gottlieb B, Jung L, Holt RJ. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2018 Jun 26;16(1):41. doi: 10.1186/s12969-018-0260-y.

Drugs

Indications